Dr. Mark T. Gladwin was named as the subsequent dean of the College of Maryland College of Medication after a nationwide search to interchange Dr. E. Albert Reece, who introduced final yr he would step down after 16 years of main the medical college.

Gladwin is a coronary heart, vascular and lung doctor and scientist, and presently serves as a professor and chair of the division of medication on the College of Pittsburgh College of Medication.

He’ll start the brand new positions of dean and vice chairman for medical affairs August 1 at a time when the Baltimore medical college has vastly elevated its analysis and medical {dollars} and its footprint. He’ll earn about $1 million a yr in wage as dean, in line with the college.

Analysis funding reached $600 million lately and medical revenues at the moment are round $350 million, with college physicians offering inpatient and outpatient care to greater than 1.5 million sufferers yearly at 62 places round Maryland. The varsity additionally maintains analysis and therapy amenities in 30 nations.

It holds 130 U.S. and 228 international patents and 205 expertise licenses and its college have made 576 scientific disclosure and began 33 firms.

The Maryland medical college grew to become identified in the course of the coronavirus pandemic for growing and testing therapies and vaccines. And in January it gained consideration for performing the primary transplant of a genetically modified pig coronary heart right into a affected person, who lived for 2 months after the surgical procedure.

“I’m very honored to have been chosen as dean of one of the crucial prestigious medical faculties within the nation,” Gladwin stated in an announcement.

“All the pieces I discovered throughout my go to to UMB furthered my want to hitch the College of Maryland College of Medication,” he stated. “I used to be already nicely conscious of its repute for excellence in training, analysis, medical care and group outreach. I stay up for listening to, and studying from UMB college, employees, and college students as we proceed the essential work of carrying the College’s mission ahead in Baltimore, across the state and around the globe.”

Story continues

Gladwin comes with an intensive medical, administration and analysis resume.

He additionally serves as affiliate dean for physician-scientist mentoring and affiliate vice chancellor for science technique, well being sciences, on the College of Pittsburgh College of Medication. He was a founding father of the Pittsburgh Coronary heart, Lung, Blood and Vascular Medication Institute.

“I couldn’t be extra happy to announce Dr. Gladwin as the subsequent dean of the College of Maryland College of Medication,” stated Dr. Bruce E. Jarrell, president of the College of Maryland, Baltimore, who introduced the appointment in a letter Tuesday to school, employees and college students. “I’m assured he’ll proceed to complement the legacy of our College of Medication and place our world-class establishment to fulfill the challenges of the long run.”

Officers stated they sought a brand new chief who might oversee tutorial and medical missions, work with the encircling Baltimore group and preserve the partnership with the College of Maryland Medical System, the affiliated 13-hospital community within the state.

Search committee members referred to as the job difficult and multifaceted and stated Gladwin had the suitable {qualifications}.

“The search committee was impressed by not solely his expertise, but additionally his imaginative and prescient for the way forward for medication and the position of the medical college in at the moment’s society,” stated Claire M. Fraser, a professor of medication and director of the Institute for Genome Sciences and chair of the search committee.

Aishwarya Iyer, an MD/PhD pupil within the College of Medication and president of the College Scholar Authorities Affiliation additionally was on the choice committee.

“I believed his analysis portfolio was phenomenal,” she stated. “He comes from a very robust establishment and has a whole lot of expertise managing his place very nicely and really effectively. I’m excited to welcome this new dean.”

Choice committee members stated Gladwin additionally would have the ability to fulfill one other want of the job, making certain variety, fairness and inclusion.

In Pittsburgh, he created a brand new vice chair place for variety and inclusion and labored with the residency director to develop a specialty observe geared toward attracting underrepresented minorities, amongst different initiatives.

That work will proceed at Maryland, the place the medical college already has undergone modifications to deal with allegations of sexual harassment and of a failure to create an equitable surroundings for ladies. In response in 2018, the college took a number of steps underneath a program referred to as Program in Cultural Transformation that included selling a number of girls to govt management positions and making a committee to make extra suggestions and assess progress.

Gladwin earned his bachelor’s and medical levels from the College of Miami and accomplished his internship and chief residency in inner medication on the Oregon Well being Science College. He accomplished a important care medication fellowship on the Nationwide Institutes of Well being and a pulmonary fellowship on the College of Washington in Seattle.

He has served in varied positions at NIH and the College of Pittsburgh, the place he was recruited in 2008 to function chief of the division of pulmonary, allergy and significant care medication and the inaugural director of the Vascular Medication Institute. He grew to become division chair in 2014 and oversaw 800 college and $300 million in medical and analysis funding.

Sickle cell analysis has been a particular focus for Gladwin for greater than twenty years. He has lots of of revealed manuscripts within the fields of vascular and nitric oxide biology and has been the principal investigator on main medical trials.

He was born in Palo Alto, California, and raised across the nation and in Ghana, Mexico and Guatemala.

Dean Reece will stay as a part of the medical college’s college and as director of a brand new Middle for Superior Analysis, Coaching and Innovation and as co-director the college’s Middle for Delivery Defects Analysis.

“On behalf of the College of Medication, I’m delighted to increase heartiest congratulations and a heat welcome to Dr Gladwin on his decanal appointment,” Reece stated in an announcement. “I’m most happy to ‘move the baton’ to him and stay up for his management within the years to return.”